Amgen Cuts The Price Of A Key Drug — Prodding A Rival Biotech To SlideInvestors Business Daily • 10/24/19
Is Regeneron Stock A Dud? Analyst Doubts Biotech's Research ProwessInvestors Business Daily • 09/24/19
Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/05/19
Is Regeneron Pharmaceuticals (REGN) A Great Pick for Value Investors?Zacks Investment Research • 08/14/19
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/06/19